Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study

Charalampos Charalampous, Shaji Kunnathu Kumar, Ricardo Parrondo, Saurabh Chhabra, Mei Sheng Duh, Priyanka Bobbili, Aolin Wang, Jingyi Chen, Manasi Mohan, Patrick Hlavacek, Jinma Ren, Alex Schepart, Guido Nador, Marco DiBonaventura

Blood (2023) 142 (Supplement 1): 6727.

https://doi.org/10.1182/blood-2023-180984

Published: 2023

Journal Articles

Infection Outcomes and Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Treated with Immunoglobulin Replacement Therapy

Jacob Soumerai, Thais Gift, Zaid Yousif, Raj Desai, Lynn Huynh, Gregory Belsky, Mei Sheng Duh, Marie Sanchirico

Blood (2023) 142 (Supplement 1): 3280.

https://doi.org/10.1182/blood-2023-179458

Published: 2023

Journal Articles

Correlation between Real-World Progression-Free Survival (rwPFS) and Overall Survival (OS) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Relapsed or Are Refractory, Intolerant, Resistant to Treatment with a Bruton's Tyrosine Kinase Inhibitor (BTKi)

Kevin H. Lin, Lynn Huynh, Xiaoqin Yang, Enrico Zanardo, Lisa Matay, Megan Pinaire, Daria Liborski, Mikaela M. McDonough, Jillian Foreman, Mohammed Z.H. Farooqui, Enrico De Nigris, Shravanthi R. Gandra, Eric M. Sarpong, Mei Sheng Duh, Jennifer R. Brown, Matthew S Davids

Blood (2023) 142 (Supplement 1): 4652.

https://doi.org/10.1182/blood-2023-180793

Published: 2023

Journal Articles

Infection Outcomes and Hypogammaglobulinemia in Patients with Non-Hodgkin Lymphoma Treated with Immunoglobulin Replacement Therapy

Jacob Soumerai, Zaid Yousif, Thais Gift, Raj Desai, Lynn Huynh, Caitlin Haven, Mei Sheng Duh, Marie Sanchirico

Blood (2023) 142 (Supplement 1): 3040.

https://doi.org/10.1182/blood-2023-187068

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Refractory to Covalent Bruton's Tyrosine Kinase Inhibitor (BTKi) and Exposed to B-Cell Lymphoma 2 Inhibitor (BCL2i)

Blood (2023) 142 (Supplement 1): 1910.

https://doi.org/10.1182/blood-2023-182188

Published: 2023

Journal Articles

Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)

Blood (2023) 142 (Supplement 1): 309.

https://doi.org/10.1182/blood-2023-174497

Published: 2023

Journal Articles

Real-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study

Enrico De Nigris, Wendy Y. Cheng, Eric M. Sarpong, Siyang Leng, Mohammed Z.H. Farooqui, Uchechukwu Samuel Agu, Maryaline Catillon, Dominique Lejeune, Nathaniel Downes, Lisa Matay, Mei Sheng Duh, Scott F. Huntington

Blood (2023) 142 (Supplement 1): 6523.

https://doi.org/10.1182/blood-2023-178660

Published: 2023

Journal Articles

Real-World Treatment Patterns and Clinical Outcomes with Brentuximab Vedotin or Other Standard Therapies in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Chart Review Study in the United States

Stefan K. Barta, Nicholas Liu, Maral DerSarkissian, Rose Chang, Mingchen Ye, Mei Sheng Duh, Andy Surinach, Michelle A. Fanale, Kristina S. Yu

Blood (2022) 140 (Supplement 1): 5167–5169.

https://doi.org/10.1182/blood-2022-162375

Published: 2022

Journal Articles

Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study

Joshua Richter, Peter Feng Wang, Alexa Molinari, Boris Gorsh, Natalie Boytsov, Suzanne Landi, Sue Perera, Prani Paka, Teresa Palumbo, Mei Sheng Duh, Christopher Yee, Anamika Khanal, Sonia Gupta, Ajai Chari

Blood (2022) 140 (Supplement 1): 4338–4340.

https://doi.org/10.1182/blood-2022-164918

Published: 2022

Journal Articles

Patient Characteristics, Treatment Patterns, and Outcomes Following Covalent Btki Discontinuation in a Contemporary Cohort of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients

Kevin H. Lin, Lynn Huynh, Xiaoqin Yang, Neema Lema, Lisa Matay, Sobana Balasubramanian, Daria Liborski, Mikaela M. McDonough, Jillian Foreman, Mohammed Z.H. Farooqui, Enrico De Nigris, Shravanthi R. Gandra, Eric Sarpong, Mei Sheng Duh, Jennifer R. Brown, Matthew S. Davids

Blood (2022) 140 (Supplement 1): 4150–4152.

https://doi.org/10.1182/blood-2022-160389

Published: 2022

Journal Articles

A Matching-Adjusted Indirect Comparison of the Efficacy of Pegcetacoplan Using Prince Trial Data Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

Raymond Wong, Jesse Fishman, Koo Wilson, Mohammed Al-Adhami, Michael Yeh, Zalmai Hakimi, Christopher Yee, Lynn Huynh, Mei Sheng Duh

Blood (2022) 140 (Supplement 1): 11435–11437.

https://doi.org/10.1182/blood-2022-160197

Published: 2022

Journal Articles

Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study

Malin Hultcrantz, David Kleinman, Ravi Vij, Fernando Escalante, Nirali Kotowsky, Jacopo Bitetti, Christine Mackay, Natalie Boytsov, Leena Camadoo-O'Byrne, Guillaume Germain, Mei Sheng Duh, François Laliberté, Malena Mahendran, Ana Urosevic, Hans C. Lee

Blood (2022) 140 (Supplement 1): 10124–10126.

https://doi.org/10.1182/blood-2022-164929

Published: 2022

Journal Articles

Comparative Effectiveness of Lenalidomide/Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/or Refractory Multiple Myeloma in Subgroups Defined By Cytogenetic Risk

Larysa Sanchez, Mu Cheng, Dasha Cherepanov, Maral DerSarkissian, Dawn Marie Stull, Fei Huang, Annalise Hilts, Justin Chun, Mei Sheng Duh, Sikander Ailawadhi

Blood (2022) 140 (Supplement 1): 4308–4309.

https://doi.org/10.1182/blood-2022-156320

Published: 2022

Journal Articles

Real-World Ravulizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population

Wendy Y. Cheng, Jesse Fishman, Sujata P. Sarda, Sangeeta Krishnan, Colin Kunzweiler, Jensen Duy Vu, Mihran Yenikomshian, Mei Sheng Duh

Blood (2021) 138 (Supplement 1): 4999.

https://doi.org/10.1182/blood-2021-153106

Published: 2021

Journal Articles

Treatment Patterns and Outcomes of Patients with Double-Class Refractory or Triple-Class Refractory Multiple Myeloma: A Retrospective US Electronic Health Record Database Study

Feng Wang, Boris Gorsh, Maral DerSarkissian, Prani Paka, Rachel Bhak, Natalie Boytsov, Miriam L. Zichlin, Leah Sansbury, Christopher W. Yee, Shannon Ferrante, Anamika Khanal, Ahmed Noman, Mei Sheng Duh

Blood (2021) 138 (Supplement 1): 2705.

https://doi.org/10.1182/blood-2021-152301

Published: 2021

Journal Articles

Time and Personnel Costs Associated with Adverse Event (AE) Management Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib, Ibrutinib, or Venetoclax

Hetalkumari Patel, Svea K. Wahlstrom, Maral DerSarkissian, Colin Kunzweiler, Felicia Castriota, Rose Chang, Hoi Ching Cheung, Yuqian Gu, Helen Guo, Mei Sheng Duh, Kellie J. Ryan

Blood (2021) 138 (Supplement 1): 2999.

https://doi.org/10.1182/blood-2021-147449

Published: 2021

Journal Articles

Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study

Steffen Koschmieder, Clemens Schulte, Eyck von der Heyde, Lambert Busque, Françoise Boyer-Perrard, Timothy Devos, Francesco Passamonti, Mike W. Zuurman, Carole Paley, Geralyn Gilotti, Wendy Y. Cheng, Chi Gao, Mu Cheng, Melody Wu, Mei Sheng Duh, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2021-148254

Published: 2021

Journal Articles

Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Previously Treated with Eculizumab: A Matching-Adjusted Indirect Comparison

Rachel Y Bhak, MS, Nikita Mody-Patel, PharmD, MBA, Scott B. Baver, PhD, Colin Kunzweiler, PhD MS, Christopher Yee, ScM, Sanjana Sundaresan, ScM, Natalia Swartz, MPH, Mei Sheng Duh, ScD, MPH, Sangeeta Krishnan, PharmD, MS, Sujata P. Sarda, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-141667

Published: 2020

Journal Articles

Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population

Wendy Y Cheng, PhD MPH, Sujata P. Sarda, PhD, Nikita Mody-Patel, PharmD, MBA, Sangeeta Krishnan, PharmD, MS, Mihran Yenikomshian, MBA, Patrick J. Scoble, PharmD, Colin Kunzweiler, PhD MS, Jensen Duy Vu, BA, Hoi Ching Cheung, BA, Mei Sheng Duh, ScD, MPH

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-141636

Published: 2020

Journal Articles

Real-World Treatment Patterns and Healthcare Resource Utilization (HRU) of Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population

Wendy Y Cheng, PhD MPH, Sujata P. Sarda, PhD, Nikita Mody-Patel, PharmD, MBA, Sangeeta Krishnan, PharmD, MS, Mihran Yenikomshian, MBA, Patrick J. Scoble, PharmD, Malena Mahendran, MSc, Dominique Lejeune, MSc, Louise Yu, MSc, Mei Sheng Duh, ScD, MPH

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-141648

Published: 2020

NARROW

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study

Infection Outcomes and Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Treated with Immunoglobulin Replacement Therapy

Correlation between Real-World Progression-Free Survival (rwPFS) and Overall Survival (OS) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Relapsed or Are Refractory, Intolerant, Resistant to Treatment with a Bruton's Tyrosine Kinase Inhibitor (BTKi)

Infection Outcomes and Hypogammaglobulinemia in Patients with Non-Hodgkin Lymphoma Treated with Immunoglobulin Replacement Therapy

Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Refractory to Covalent Bruton's Tyrosine Kinase Inhibitor (BTKi) and Exposed to B-Cell Lymphoma 2 Inhibitor (BCL2i)

Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)

Real-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study

Real-World Treatment Patterns and Clinical Outcomes with Brentuximab Vedotin or Other Standard Therapies in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Chart Review Study in the United States

Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study

Patient Characteristics, Treatment Patterns, and Outcomes Following Covalent Btki Discontinuation in a Contemporary Cohort of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients

A Matching-Adjusted Indirect Comparison of the Efficacy of Pegcetacoplan Using Prince Trial Data Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study

Comparative Effectiveness of Lenalidomide/Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/or Refractory Multiple Myeloma in Subgroups Defined By Cytogenetic Risk

Real-World Ravulizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population

Treatment Patterns and Outcomes of Patients with Double-Class Refractory or Triple-Class Refractory Multiple Myeloma: A Retrospective US Electronic Health Record Database Study

Time and Personnel Costs Associated with Adverse Event (AE) Management Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib, Ibrutinib, or Venetoclax

Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study

Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Previously Treated with Eculizumab: A Matching-Adjusted Indirect Comparison

Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population

Real-World Treatment Patterns and Healthcare Resource Utilization (HRU) of Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only